It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cancer metabolism is rewired to support cell survival in response to intrinsic and environmental stressors. Identification of strategies to target these adaptions is an area of active research. We previously described a cytosolic aspartate aminotransaminase (GOT1)-driven pathway in pancreatic cancer used to maintain redox balance. Here, we sought to identify metabolic dependencies following GOT1 inhibition to exploit this feature of pancreatic cancer and to provide additional insight into regulation of redox metabolism. Using pharmacological methods, we identify cysteine, glutathione, and lipid antioxidant function as metabolic vulnerabilities following GOT1 withdrawal. We demonstrate that targeting any of these pathways triggers ferroptosis, an oxidative, iron-dependent form of cell death, in GOT1 knockdown cells. Mechanistically, we reveal that GOT1 inhibition represses mitochondrial metabolism and promotes a catabolic state. Consequently, we find that this enhances labile iron availability through autophagy, which potentiates the activity of ferroptotic stimuli. Overall, our study identifies a biochemical connection between GOT1, iron regulation, and ferroptosis.
The aspartate aminotransaminase GOT1 is important for maintaining redox balance. Here, the authors show that inhibition of GOT1 in pancreatic cancer cells leads to cell death via ferroptosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 University of Michigan, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Graduate Program in Chemical Biology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
2 University of Michigan, Graduate Program in Cancer Biology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
3 University of Michigan, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
4 University of Michigan, Immunology Graduate Program, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
5 University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
6 University of Michigan, Department of Biostatistics, School of Public Health, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Rogel Cancer Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
7 University of Michigan, Rogel Cancer Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
8 University of Texas Southwestern Medical Center, Medical Scientist Training Program, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
9 Columbia University Medical Center, Division of Digestive and Liver Diseases, Department of Medicine, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
10 Columbia University Medical Center, Division of Digestive and Liver Diseases, Department of Medicine, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Medical Center, Department of Pathology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
11 Beth Israel Deaconess Medical Center, Division of Signal Transduction and Mass Spectrometry Core, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
12 University of Texas Southwestern Medical Center, Children’s Medical Center Research Institute and Department of Pediatrics, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
13 University of Michigan, Rogel Cancer Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Department of Surgery, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Department of Cell and Developmental Biology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
14 University of Michigan, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Rogel Cancer Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
15 University of Michigan, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan, Rogel Cancer Center, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)